Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net loss	$ (5,054,772)	$ (6,497,519)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	86,104	185,492
Accretion of interest on NuvoGen obligation	(2,747)	(2,983)
Write off deferred offering costs	80,692	0
Provision for excess inventory	409,670	59,353
Amortization of SVB Term Loan discount and issuance costs	71,832	117,727
Stock-based compensation expense	129,332	251,214
Employee stock purchase plan expense	7,776	16,591
Non-cash operating lease expense	114,517	100,316
Accrued interest on available-for-sale securities investments	(27,183)	(5,128)
Changes in operating assets and liabilities:
Accounts receivable	289,715	1,343,246
Inventory	5,511	(120,164)
Prepaid expenses and other	278,042	93,299
Accounts payable	(25,921)	(352,934)
Accrued liabilities	(571,519)	(1,069,543)
Contract liabilities	(38,394)	40,279
Operating lease liabilities	(116,246)	(98,809)
Net cash used in operating activities	(4,363,591)	(5,939,563)
Investing activities
Purchase of property and equipment	(6,238)	(8,415)
Maturities of available-for-sale securities	0	5,400,000
Purchase of available-for-sale securities	(3,538,390)	0
Net cash (used in) provided by investing activities	(3,544,628)	5,391,585
Financing activities
Proceeds from March 2022 Securities Purchase Agreement, net of issuance costs of $0.4 million	0	7,207,499
Payments on SVB Term Loan	(808,824)	(1,250,000)
Payments of December 2022 Securities Purchase Agreement issuance costs	(350,523)	0
Payments on NuvoGen obligation	(146,032)	(172,624)
Payments of deferred offering costs	0	(38,500)
Payments on financing leases	(3,866)	(4,635)
Taxes paid for net share settlement of restricted stock awards	(215)	(8,129)
Cash in lieu of fractional shares related to reverse stock split	(640)	0
Payments on 2021 insurance note	0	(167,586)
Net cash (used in) provided by financing activities	(1,310,100)	5,566,025
Effect of exchange rates on cash	3,871	(3,570)
(Decrease) increase in cash and cash equivalents	(9,214,448)	5,014,477
Cash and cash equivalents at beginning of period	12,210,857	9,599,950
Cash and cash equivalents at end of period	2,996,409	14,614,427
Supplemental disclosure of noncash investing and financing activities
Net reclassification of instruments from inventory to property and equipment, net	16,625	0
Deferred financing costs payable and accrued at period end	0	98,713
Issuance costs payable at period end	447
Disposal of fully depreciated assets	177,451	0
Issuance of common stock upon conversion of Series A convertible preferred stock	0	1,402,430
Supplemental cash flow information
Cash paid for interest	74,976	139,846
Cash paid for taxes	$ 1,838	$ 0